313 related articles for article (PubMed ID: 37328828)
1. AXL in cancer: a modulator of drug resistance and therapeutic target.
Tang Y; Zang H; Wen Q; Fan S
J Exp Clin Cancer Res; 2023 Jun; 42(1):148. PubMed ID: 37328828
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
3. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
4. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
[TBL] [Abstract][Full Text] [Related]
6. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis.
Gao L; He C; Yang A; Zhou H; Lu Q; Birge RB; Wu Y
Cell Commun Signal; 2023 Aug; 21(1):195. PubMed ID: 37537628
[TBL] [Abstract][Full Text] [Related]
8. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
[TBL] [Abstract][Full Text] [Related]
9. TAM family kinases as therapeutic targets at the interface of cancer and immunity.
DeRyckere D; Huelse JM; Earp HS; Graham DK
Nat Rev Clin Oncol; 2023 Nov; 20(11):755-779. PubMed ID: 37667010
[TBL] [Abstract][Full Text] [Related]
10. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
Schoumacher M; Burbridge M
Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of the functionally elusive TAM receptor family.
Miao YR; Rankin EB; Giaccia AJ
Nat Rev Drug Discov; 2024 Mar; 23(3):201-217. PubMed ID: 38092952
[TBL] [Abstract][Full Text] [Related]
12. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV; Amend SR; Pienta KJ
Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
[TBL] [Abstract][Full Text] [Related]
13. Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells.
Lu Y; Wan J; Yang Z; Lei X; Niu Q; Jiang L; Passtoors WM; Zang A; Fraering PC; Wu F
FASEB J; 2017 Apr; 31(4):1382-1397. PubMed ID: 28034848
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
[TBL] [Abstract][Full Text] [Related]
15. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
Kong D; Tian Q; Chen Z; Zheng H; Stashko MA; Yan D; Earp HS; Frye SV; DeRyckere D; Kireev D; Graham DK; Wang X
J Med Chem; 2024 Apr; 67(7):5866-5882. PubMed ID: 38556760
[TBL] [Abstract][Full Text] [Related]
17. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
18. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Dufour F; Silina L; Neyret-Kahn H; Moreno-Vega A; Krucker C; Karboul N; Dorland-Galliot M; Maillé P; Chapeaublanc E; Allory Y; Stransky N; Haegel H; Menguy T; Duong V; Radvanyi F; Bernard-Pierrot I
Br J Cancer; 2019 Mar; 120(5):555-564. PubMed ID: 30765874
[TBL] [Abstract][Full Text] [Related]
19. Targeting Axl and Mer kinases in cancer.
Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
[TBL] [Abstract][Full Text] [Related]
20. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]